Literature DB >> 23170986

The MSH2 c.388_389del mutation shows a founder effect in Portuguese Lynch syndrome families.

M Pinheiro1, C Pinto, A Peixoto, I Veiga, B Mesquita, R Henrique, P Lopes, O Sousa, M Fragoso, L M Dias, M Baptista, C Marinho, E Mangold, C Vaccaro, D G Evans, S Farrington, M G Dunlop, M R Teixeira.   

Abstract

The MSH2 c.388_389del mutation has occasionally been described in Lynch families worldwide. At the Portuguese Oncology Institute in Porto, Portugal, we have identified 16 seemingly unrelated families with this germline mutation. To evaluate if this alteration is a founder or a recurrent mutation we performed haplotype analysis in the 16 Portuguese index cases and 55 relatives, as well as in four index cases and 13 relatives reported from Germany, Scotland, England, and Argentina. In the Portuguese families we observed a shared haplotype of approximately 10 Mb and all were originated from the north of Portugal. These results suggest that this alteration is a founder mutation in Portugal with a relatively recent origin. In the reported families outside Portugal with this mutation different haplotype backgrounds were observed, supporting the hypothesis that it occurred de novo on multiple occasions. We also conclude that the high proportion of families with the MSH2 c.388_389del mutation indicates that screening for this alteration as a first step may be cost-effective in the genetic testing of Lynch syndrome suspects of Portuguese ancestry, especially those originating from the north of Portugal.
© 2012 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Lynch syndrome; MSH2; founder mutation; recurrent mutation

Mesh:

Substances:

Year:  2012        PMID: 23170986     DOI: 10.1111/cge.12062

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  7 in total

1.  The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.

Authors:  Sofia Maia; Marta Cardoso; Paula Paulo; Manuela Pinheiro; Pedro Pinto; Catarina Santos; Carla Pinto; Ana Peixoto; Rui Henrique; Manuel R Teixeira
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

2.  Co-occurrence of nonsense mutations in MSH6 and MSH2 in Lynch syndrome families evidencing that not all truncating mutations are equal.

Authors:  Carla Pinto; Manuela Pinheiro; Ana Peixoto; Catarina Santos; Isabel Veiga; Patrícia Rocha; Pedro Pinto; Paula Lopes; Manuela Baptista; Rui Henrique; Manuel R Teixeira
Journal:  J Hum Genet       Date:  2015-10-08       Impact factor: 3.172

3.  Comparison of multiple genotyping methods for the identification of the cancer predisposing founder mutation p.R337H in TP53.

Authors:  Mariana Fitarelli-Kiehl; Gabriel S Macedo; Rosane Paixão Schlatter; Patricia Koehler-Santos; Ursula da Silveira Matte; Patricia Ashton-Prolla; Juliana Giacomazzi
Journal:  Genet Mol Biol       Date:  2016-06-03       Impact factor: 1.771

4.  A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America.

Authors:  Benedito Mauro Rossi; Edenir Inêz Palmero; Francisco López-Kostner; Carlos Sarroca; Carlos Alberto Vaccaro; Florencia Spirandelli; Patricia Ashton-Prolla; Yenni Rodriguez; Henrique de Campos Reis Galvão; Rui Manuel Reis; André Escremim de Paula; Luis Gustavo Capochin Romagnolo; Karin Alvarez; Adriana Della Valle; Florencia Neffa; Pablo German Kalfayan; Enrique Spirandelli; Sergio Chialina; Melva Gutiérrez Angulo; Maria Del Carmen Castro-Mujica; Julio Sanchez de Monte; Richard Quispe; Sabrina Daniela da Silva; Norma Teresa Rossi; Claudia Barletta-Carrillo; Susana Revollo; Ximena Taborga; L Lena Morillas; Hélène Tubeuf; Erika Maria Monteiro-Santos; Tamara Alejandra Piñero; Constantino Dominguez-Barrera; Patrik Wernhoff; Alexandra Martins; Eivind Hovig; Pål Møller; Mev Dominguez-Valentin
Journal:  BMC Cancer       Date:  2017-09-05       Impact factor: 4.430

5.  Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation.

Authors:  Jenny von Salomé; Tao Liu; Markku Keihäs; Moni Morak; Elke Holinski-Feder; Ian R Berry; Jukka S Moilanen; Stéphanie Baert-Desurmont; Annika Lindblom; Kristina Lagerstedt-Robinson
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

6.  Ancestry of the Brazilian TP53 c.1010G>A (p.Arg337His, R337H) Founder Mutation: Clues from Haplotyping of Short Tandem Repeats on Chromosome 17p.

Authors:  Diego Davila Paskulin; Juliana Giacomazzi; Maria Isabel Achatz; Sandra Costa; Rui Manoel Reis; Pierre Hainaut; Sidney Emanuel Batista dos Santos; Patricia Ashton-Prolla
Journal:  PLoS One       Date:  2015-11-30       Impact factor: 3.240

7.  Target gene mutational pattern in Lynch syndrome colorectal carcinomas according to tumour location and germline mutation.

Authors:  Manuela Pinheiro; Carla Pinto; Ana Peixoto; Isabel Veiga; Paula Lopes; Rui Henrique; Helena Baldaia; Fátima Carneiro; Raquel Seruca; Ian Tomlinson; Michal Kovac; Karl Heinimann; Manuel R Teixeira
Journal:  Br J Cancer       Date:  2015-08-06       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.